You Ruilian, Zheng Hua, Xu Lubin, Ma Tiantian, Chen Gang, Xia Peng, Fan Xiaohong, Ji Peili, Wang Li, Chen Limeng
Department of Nephrology, Peking Union Medical College Hospital, No 1, Shuaifuyuan, Wangfujing St, Beijing, 100730, China.
Department of Epidemiology and Biostatistics, Institute of Basic Medical Sciences, Chinese Academy of Medical Sciences, School of Basic Medicine, Peking Union Medical College, Beijing, 100005, China.
J Intensive Care. 2021 Nov 15;9(1):70. doi: 10.1186/s40560-021-00584-2.
Urinary uromodulin (uUMOD) is one of the novel biomarkers for predicting AKI. However, currently available publications showed inconsistent results. We designed this meta-analysis to evaluate the potential association between uUMOD and AKI.
We searched research articles with no language restriction in Medline, Web of Science, Cochrane Library, Embase, and 3 Chinese datasets from inception to February 2021. We used random-effects models to estimate the standardized mean difference (SMD) between patients with AKI or not, while the leave-one-out method and random-effects meta-regression to evaluate the sensitivity and the impact of potential confounders such as age and surgery.
The meta-analysis comprising 3148 subjects from 11 studies showed that the uUMOD of the AKI group is significantly lower than the non-AKI group (SMD: - 0.71; 95% confidence interval (CI), - 1.00, - 0.42, P < 0. 001, I = 78.8%). Subgroup analysis revealed the difference is also significant in a different age, surgery condition, and assay time but not acute rejection (AR) group, especially in children (SMD: - 1.21, 95% CI: - 1.80, - 0.61; P < 0.001) and patients undergoing surgery (SMD: - 1.03, 95% CI: - 1.75, - 0.30; P < 0.001). Lower uromodulin is associated with higher odds for AKI incidence (odds ratio = 2.47, 95% CI: 1.12, 5.47; P < 0.001, I = 89%). Meta-reggression found that age was associated with the SMD of uUMOD. The study outcome was reliably confirmed by the sensitivity analysis.
The present study suggested a negative association between uUMOD and AKI especially in children and surgical patients.
尿调节素(uUMOD)是预测急性肾损伤(AKI)的新型生物标志物之一。然而,目前已发表的文献结果并不一致。我们设计了这项荟萃分析,以评估uUMOD与AKI之间的潜在关联。
我们检索了Medline、Web of Science、Cochrane图书馆、Embase以及3个中文数据集,不限语言,检索时间从数据库建立至2021年2月。我们使用随机效应模型来估计AKI患者与非AKI患者之间的标准化平均差异(SMD),同时采用逐一剔除法和随机效应荟萃回归来评估敏感性以及年龄和手术等潜在混杂因素的影响。
这项包含11项研究中3148名受试者的荟萃分析表明,AKI组的uUMOD显著低于非AKI组(SMD:-0.71;95%置信区间(CI),-1.00,-0.42,P<0.001,I² = 78.8%)。亚组分析显示,在不同年龄、手术情况和检测时间下差异也很显著,但在急性排斥反应(AR)组中不显著,尤其是在儿童(SMD:-1.21,95%CI:-1.80,-0.61;P<0.001)和接受手术的患者中(SMD:-1.03,95%CI:-1.75,-0.30;P<0.001)。较低的尿调节素与AKI发生率较高相关(比值比 = 2.47,95%CI:1.12,5.47;P<0.001,I² = 89%)。荟萃回归发现年龄与uUMOD的SMD相关。敏感性分析可靠地证实了研究结果。
本研究表明uUMOD与AKI之间存在负相关,尤其是在儿童和手术患者中。